Ann: Clinical & Functional Validation of HeraBEAT Achieved at JHC, page-10

this is just my take on charts..

we have a company making proposition about to start. If that commercialises properly then the reliance on prior charting data is redundant. We are in a completely new phase as a company and will fly a bit blind as people jump on board. If it all goes to plan over 2-3 years then a new set of data will form the next phase of our charts. My target is $40m MC followed by $85m and then if all is going well we will move to around $400m. Capital raises and dilution will affect the share price but those are the targets I’m aiming for.

Over $50m we become open to more than just Altor or Etchell capital in terms of institutional interests. Over $100m we end up on Perennial and Bennelong type screens. Over $250m we are a real investment grade business that has multiple institutions. I’m happy to be at 1.3m shares for this ride, I’ll look at the bank account today and maybe go longer